Phase 2 of Neovasc's TIARA-II Study to Commence in Germany and the United Kingdom
January 29, 2019—Neovasc Inc. announced that it has completed the phase 1 requirements of the TIARA-II study required by the biphasic study design in both Germany and the United Kingdom. The company has received approval to proceed with phase 2 of the TIARA-II study for its Tiara transcatheter mitral valve replacement device. The approval will allow the TIARA-II study to proceed in these geographies with no restrictions.
According to the company, this approval comes after adjudication of adverse events by the Clinical Events Committee as well as Data and Safety Monitoring Board review of the data, and governmental regulatory and ethics committee reviews of the interim clinical report provided for 20 patients receiving implants.
The TIARA-II study is an international, multicenter, single-arm, prospective, nonrandomized, safety and performance clinical study. The total enrollment goal for the study in all geographies is 115 implanted subjects.
Tiara is a self-expanding mitral bioprosthesis designed to treat mitral valve regurgitation by replacing the diseased valve. The Tiara valve is currently being evaluated in the TIARA I early feasibility trial in the United States, Canada, and Belgium, and in the TIARA II European CE Mark trial in Germany, Italy, and the United Kingdom.
advertisement
Featured Video
Evolut™ PRO System
Sponsored by Medtronic
Related Articles
Top 5 Articles From October 2018
CT Assessment Before TMVR
By Moderator: Dee Dee Wang, MD, FACC, FASE, FSCCT
Panel: Mayra Guerrero, MD; and Marco Barbanti, MD
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Shakeel A. Qureshi, MD, FRCP, FRCPCH
Peripheral Vascular Programs Could Improve Population Health and Grow Volumes
An overview of the steps involved in developing a PAD program to address this underserved patient population.
By Ginger Biesbrock, PA-C, MPH, MPAS, AACC; and Joel Sauer, MBA
Complicated Radial Access During Primary PCI
By Moderator: Pieter C. Smits, MD, PhD, FESC
Panel: Mohamed Abdel-Wahab, MD, FESC; Peter W. Danse, MD; and Valeria Paradies, MD
Planning for Transcatheter Aortic Valve Replacement
By Moderator: Mauricio G. Cohen, MD, FACC, FSCAI
Panel: Santiago Garcia, MD, FACC, FSCAI; William O’Neill, MD; and Molly Szerlip, MD, FACC, FSCAI
Top 5 from EVToday's Current Issue
Anticipating the 2019 AAA NICE Guidelines
Prof. Loftus shares his thoughts on the impending publication of the UK’s NICE updated guidelines for abdominal aortic aneurysm treatment and the potential effects they may have on practice and patients.
With Ian M. Loftus, MD, FRCS
Genetics and Hereditary Factors of Aortic Disease: Applying What We Know, Exploring What We Don’t
A discussion on the current landscape of genetics research related to diagnosing and treating aortic disease.
